BEST1 and Best vitelliform macular dystrophy: In regards to BVMD, RPE derived from autologous iPSC would carry the same pathogenic variant in BEST1, and thus CRISPR/Cas9 gene editing technologies would be necessary to correct this variant in the iPSC-RPE cells34.